AnalystsSerge BelangerSerge Belanger's Stock Forecasts
AnalystsSerge Belanger
Analyst Ranking
Top 2%
#61 out of 5342 analysts
Average Return
+21.84%
Win Rate
55%238 out of 432
Risk vs Reward
Poor
Good
Serge Belanger's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Trevi Therapeutics IncTRVI | +426.92% | $2.60 | $13.70 | 2024-12-04 - 2025-12-03 | Buy |
Liquidia CorpLQDA | +337.57% | $14.18 | $62.03 | 2025-05-28 - 2026-05-27 | Buy |
Arcutis Biotherapeutics IncARQT | +297.44% | $2.34 | $9.30 | 2023-11-06 - 2024-11-05 | Buy |
Arcutis Biotherapeutics IncARQT | +297.44% | $2.34 | $9.30 | 2023-11-06 - 2024-11-05 | Buy |
Trevi Therapeutics IncTRVI | +278.35% | $2.91 | $11.01 | 2024-11-08 - 2025-11-07 | Buy |
Serge Belanger Analyst Color
Get additional color on Serge Belanger's coverage of popular stocks
Serge Belanger's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Veradermics IncMANE | 2 | Buy | $164.00 | +52.87% | Maintains | 21 days ago |
Viridian Therapeutics IncVRDN | 24 | Buy | $34.00 | +63.15% | Maintains | a month ago |
Cytokinetics IncCYTK | 29 | Buy | $102.00 | +29.75% | Reiterates | 2 months ago |
Oculis Holding AgOCS | 5 | Buy | $38.00 | +216.93% | Maintains | 2 months ago |
Trevi Therapeutics IncTRVI | 23 | Buy | $23.00 | +22.67% | Reiterates | 3 months ago |
Moonlake ImmunotherapeuticsMLTX | 16 | Buy | $30.00 | +67.32% | Maintains | 3 months ago |
Liquidia CorpLQDA | 36 | Buy | $70.00 | -20.80% | Maintains | 3 months ago |
Xenon Pharmaceuticals IncXENE | 16 | Buy | $78.00 | +21.86% | Maintains | 3 months ago |
Arcutis Biotherapeutics IncARQT | 26 | Buy | $36.00 | +38.30% | Reiterates | 3 months ago |
Biocryst Pharmaceuticals IncBCRX | 19 | Buy | $16.00 | +77.38% | Maintains | 3 months ago |
Ocular Therapeutix IncOCUL | 8 | Buy | $18.00 | +109.55% | Reiterates | 3 months ago |
Pacira Biosciences IncPCRX | 29 | Buy | $32.00 | +15.86% | Maintains | 3 months ago |
Cormedix IncCRMD | 22 | Buy | $15.00 | +99.47% | Maintains | 3 months ago |
Kalvista Pharmaceuticals IncKALV | 23 | Buy | $36.00 | +33.33% | Maintains | 4 months ago |
Collegium Pharmaceutical IncCOLL | 25 | Buy | $56.00 | +56.73% | Reiterates | 5 months ago |
Esperion Therapeutics IncESPR | 21 | Buy | $5.00 | +57.23% | Maintains | 5 months ago |
Amphastar Pharmaceuticals IncAMPH | 4 | Buy | $30.00 | +50.75% | Maintains | 5 months ago |
Newamsterdam Pharma Co NvNAMS | 11 | Buy | $48.00 | +74.23% | Maintains | 6 months ago |
Heron Therapeutics IncHRTX | 21 | Buy | $3.00 | +487.08% | Maintains | a year ago |
Evolus IncEOLS | 16 | Hold | $22.00 | +259.48% | Downgrades | a year ago |
Clearside Biomedical IncCLSDQ | 16 | Hold | $45.00 | N/A | Downgrades | a year ago |
Verrica Pharmaceuticals IncVRCA | 14 | Hold | $120.00 | N/A | Downgrades | 2 years ago |
Revance Therapeutics IncRVNC | 16 | Buy | $12.00 | N/A | Reiterates | 2 years ago |
Dice Therapeutics IncDICE | 1 | Buy | $56.00 | N/A | Reiterates | 3 years ago |
Tricida IncTCDAQ | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Phasebio Pharmaceuticals IncPHASQ | 3 | Hold | N/A | N/A | Downgrades | 4 years ago |
Aerie Pharmaceuticals IncAERI | 5 | Hold | N/A | N/A | Downgrades | 4 years ago |
Clarus Therapeutics Holdings IncCRXTQ | 4 | Hold | N/A | N/A | Downgrades | 4 years ago |
Akebia Therapeutics IncAKBA | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Zogenix IncZGNX | 3 | Hold | N/A | N/A | Downgrades | 5 years ago |
Flexion Therapeutics IncFLXN1 | 1 | Buy | $18.00 | N/A | Maintains | 5 years ago |
Calcimedica IncCALC | 2 | Hold | N/A | N/A | Downgrades | 5 years ago |
Gw Pharmaceuticals PLCGWPH | 3 | Hold | N/A | N/A | Downgrades | 6 years ago |
Zynerba Pharmaceuticals IncZYNE | 1 | Hold | N/A | N/A | Downgrades | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.